Sequenom, Inc. SQNM, a life
sciences company providing innovative genetic analysis solutions, today
announced that its wholly owned subsidiary, the Sequenom Center for Molecular
Medicine (Sequenom CMM), has completed the build-out and validation of an
additional laboratory location in Raleigh-Durham, NC, and is now processing
patient samples commercially. This new laboratory location adds capacity and
redundancy to the existing Sequenom CMM laboratory locations in California and
Michigan.
With an initial capacity of 100,000 tests per year, the North Carolina
facility will primarily support processing of the MaterniT21 PLUS
laboratory-developed test (LDT) and will immediately increase Sequenom CMM's
total MaterniT21 PLUS testing capacity to over 300,000 test samples per year.
This practice-changing prenatal LDT analyzes the relative amount of chromosome
21, 18, and 13, as well as X and Y material in cell-free fetal DNA obtained
from a maternal blood sample as early as 10 weeks of pregnancy.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in